Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
30
CSBTF Quote, Financials, Valuation and Earnings
Last price:
$32.00
Seasonality move
:
0.97%
Day range:
$32.00 - $32.00
52-week range:
$19.44 - $42.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.78x
P/B ratio:
20.91x
Volume:
250
Avg. volume:
40
1-year change:
38.53%
Market cap:
$1.3B
Revenue:
$85.8M
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Kuros Biosciences Ltd. has -- downside to fair value with a price target of -- per share.
CSBTF vs. S&P 500
-
Over the past 5 trading days, Kuros Biosciences Ltd. has overperformed the S&P 500 by 0.14% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kuros Biosciences Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kuros Biosciences Ltd. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Kuros Biosciences Ltd. reported revenues of --.
Earnings Growth
-
Kuros Biosciences Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kuros Biosciences Ltd. reported earnings per share of --.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
9.78x
EV / EBIT:
259.75x
EV / Revenue:
10.11x
PEG ratio (5yr expected):
-0.25x
EV / Free cash flow:
-1,286.38x
Price / Operating cash flow:
543.07x
Enterprise value / EBITDA:
154.40x
Gross Profit (TTM):
$108.8M
Return On Assets:
-4.79%
Net Income Margin (TTM):
-5.16%
Return On Equity:
-6.35%
Return On Invested Capital:
-6.35%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $268.4K | $276.8K | |
| Gross Profit | -- | -- | -- | $248K | $251.4K | |
| Operating Income | -- | -- | -- | -$6M | -$9M | |
| EBITDA | -- | -- | -- | -$6M | -$9M | |
| Diluted EPS | -- | -- | -- | -$16.03 | -$33.09 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $34.2M | $33.8M | $30.1M | $37M | -- | |
| Total Assets | $101.5M | $92.5M | $87M | $86M | -- | |
| Current Liabilities | $4.1M | $13.9M | $13.4M | $13.5M | -- | |
| Total Liabilities | $9.3M | $15.8M | $15.9M | $19.1M | -- | |
| Total Equity | $92.2M | $76.7M | $71.1M | $66.9M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$5.5M | -$5.6M | |
| Cash From Investing | -- | -- | -- | $125.6K | $170.9K | |
| Cash From Financing | -- | -- | -- | -$32K | $33.5M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
CSBTF
Sector
Market Cap
$1.3B
$23.4M
Price % of 52-Week High
74.75%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-0.2%
-1.64%
1-Year Price Total Return
38.53%
-21.81%
Beta (5-Year)
0.913
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$31.92
200-day SMA
Sell
Level
$34.55
Bollinger Bands (100)
Sell
Level
32.87 - 39.33
Chaikin Money Flow
Buy
Level
13.5K
20-day SMA
Sell
Level
$33.84
Relative Strength Index (RSI14)
Sell
Level
9.26
ADX Line
Sell
Level
64.09
Williams %R
Buy
Level
-96.8037
50-day SMA
Sell
Level
$36.52
MACD (12, 26)
Sell
Level
-1.49
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
271.6K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.2506)
Buy
CA Score
(Annual)
Level (0.834)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.2868)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.
Stock Forecast FAQ
In the current month, CSBTF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CSBTF average analyst price target in the past 3 months is --.
-
Where Will Kuros Biosciences Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kuros Biosciences Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Kuros Biosciences Ltd.?
Analysts are divided on their view about Kuros Biosciences Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kuros Biosciences Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Kuros Biosciences Ltd.'s Price Target?
The price target for Kuros Biosciences Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CSBTF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kuros Biosciences Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CSBTF?
You can purchase shares of Kuros Biosciences Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kuros Biosciences Ltd. shares.
-
What Is The Kuros Biosciences Ltd. Share Price Today?
Kuros Biosciences Ltd. was last trading at $32.00 per share. This represents the most recent stock quote for Kuros Biosciences Ltd.. Yesterday, Kuros Biosciences Ltd. closed at $32.00 per share.
-
How To Buy Kuros Biosciences Ltd. Stock Online?
In order to purchase Kuros Biosciences Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CSBTF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CSBTF
Sector
P/E ratio
--
23.34x
PEG ratio
-0.25x
-0.01x
P/B ratio
20.91x
1.72x
Price / LTM sales
9.78x
1.51x
Growth Metrics
CSBTF
Sector
Revenue growth
--
3.21%
Earnings growth
--
10.12%
Revenue (5-year growth)
101.59%
6.27%
Earnings forecast
--
-$0.19
Profitability
CSBTF
Sector
Profitability FY 2024
$75.5M
$2.7M
Return on invested capital
-6.35%
-33.62%
Return on assets
-4.79%
-29.68%
Return on equity
-6.35%
-38.89%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Nov
13
Balance Sheet
CSBTF
Sector
Total cash
$19.3M
$25M
Short term investments
--
$23.9M
Total assets
$97.4M
$72.8M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
